NeuroNOS adds Nobel laureate to advisory board

BOSTON - NeuroNOS, a biopharmaceutical subsidiary of Beyond Air (NASDAQ: XAIR), has announced the appointment of Nobel Prize laureate Professor Dan Shechtman to its Scientific Advisory Board (SAB), enhancing its research capabilities in developing treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD). Professor Shechtman joins another Nobel laureate, Professor Roger Kornberg, in advising the company.

The company is known for its focus on complex neurological disorders, utilizing a proprietary platform that integrates behavioral techniques, artificial intelligence, and wet lab capabilities. Preclinical studies have shown promise in the platform’s ability to advance treatment methods for neuropsychiatric and neurodegenerative diseases.

NeuroNOS is currently conducting key preclinical studies to support an Investigational New Drug (IND) application to the Food and Drug Administration (FDA), with plans to initiate first-in-human clinical trials for ASD in the United States in 2026.

Professor Shechtman, awarded the Nobel Prize in Chemistry in 2011, brings a wealth of knowledge in materials science and structural chemistry. His expertise is expected to advance the company’s lead drug candidate, BA-102, through its development phases.

NeuroNOS specializes in creating therapies that regulate Nitric Oxide (NO) levels in the brain, a crucial factor in maintaining normal brain function. Elevated NO levels have been found in individuals with ASD and those suffering from AD and brain cancers. The company aims to improve the lives of those affected by these conditions through its innovative treatments.

Beyond Air, the parent company of NeuroNOS, is a commercial stage medical device and biopharmaceutical company. It has received FDA approval for its LungFit® PH system for treating hypoxic respiratory failure in neonates and is advancing clinical trials for other severe lung infections. The company’s stock has shown recent momentum with an 8.8% return over the past week, though it maintains a moderate debt level with a debt-to-capital ratio of 0.34. InvestingPro analysis reveals 12 additional key insights about Beyond Air’s financial health and growth prospects, available to subscribers.

This appointment of Professor Shechtman to the SAB is expected to significantly contribute to NeuroNOS’s efforts in translating science into impactful treatments. The information in this article is based on a press release statement from Beyond Air.

In other recent news, Beyond Air has reported a notable increase in its third-quarter fiscal year 2025 revenue, reaching $1.1 million, a 175% year-over-year growth. The company’s revenue exceeded analyst forecasts, marking a significant achievement in its financial performance. Additionally, Beyond Air has expanded its global footprint by securing new distribution agreements for its LungFit PH system in France, Turkey, Romania, and Morocco, broadening its reach to 18 countries. The system, which simplifies nitric oxide delivery, has received CE Mark approval, further enhancing its international market presence. In terms of financial strategy, Beyond Air announced an at-the-market offering to potentially sell up to $35 million of its common stock, allowing for greater financial flexibility. Analyst firm BTIG has maintained a Neutral rating on Beyond Air, despite the company’s revenue surpassing expectations, indicating cautious optimism about its future performance. Meanwhile, NeuroNOS, a subsidiary of Beyond Air, has made strides in Alzheimer’s disease research, identifying a new mechanism that could lead to novel treatments. These developments reflect Beyond Air’s ongoing efforts to innovate and expand in the medical device and biopharmaceutical sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.